Gustave Roussy

448 currently recruiting clinical trials
Create patient profile for matching
Phase 1 / Phase 2 Pancreas cancer #NCT06710132
Adenocarcinoma Locally Advanced Metastatic 1 2 Chemotherapy
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
EMD Serono Research & Development Institute, Inc.
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer #NCT06162221
Locally Advanced Metastatic KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer #NCT05563220
HER2 Negative HR Positive Locally Advanced Metastatic 1 2 Hormone therapy
Chemotherapy
Gustave Roussy (Villejuif)
Stemline Therapeutics, Inc.
Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06710132
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic 1 2 Chemotherapy
HER2 Systemic Treatment-Naive
Gustave Roussy (Villejuif)
EMD Serono Research & Development Institute, Inc.
Phase 1 Colon cancer Rectal cancer #NCT03715933
Cohortes d'expansion en Combination adénocarcome colorectal
Adenocarcinoma Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Inhibrx Biosciences, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT06551142 #2024-513663-10
Phase 1a
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
GlaxoSmithKline
Phase 1 Sarcoma and GIST #NCT03715933 #2023-508139-29-00
Cohorte sarcome d'Ewing
Bone sarcoma Ewing tumor Locally Advanced Metastatic 1 2
Gustave Roussy (Villejuif)
Inhibrx Biosciences, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07094204 #2025-522082-29-00
Escalade de dose monothérapie
Locally Advanced Metastatic Metastatic Castration-resistant Other KRAS KRAS G12C KRAS G12D KRAS non G12C 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Astellas Pharma Développement mondial, Inc.
Phase 1 Pancreas cancer #NCT07094204 #2025-522082-29-00
Cohorte extension de dose PDAC
Adenocarcinoma Locally Advanced Metastatic Other KRAS KRAS G12C KRAS non G12C KRAS G12D 1 2 Chemotherapy
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Astellas Pharma Développement mondial, Inc.
Phase 1 Lung cancer #NCT07094204 #2025-522082-29-00
Cohorte extension de dose CPNPC
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic Other KRAS KRAS G12C KRAS non G12C KRAS G12D 1 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Astellas Pharma Développement mondial, Inc.